ライフサイエンスコーパス: immune globulin

1 ed, we evaluated the efficacy of intravenous immune globulin.

2 therapy with ganciclovir and cytomegalovirus immune globulin.

3 th entecavir monotherapy without hepatitis B immune globulin.

4 r, and easier to administer than intravenous immune globulin.

5 y) without the adjunctive use of hepatitis B immune globulin.

6 of early clinical trials with intravenous Rh immune globulin.

7 ids, intravenous immunoglobulin G, or anti-D immune globulin.

8 f the 72 children were receiving intravenous immune globulin.

9 tient received variable doses of hepatitis B immune globulin.

10 ng the recommended number of doses of rabies immune globulin.

11 who had not previously received intravenous immune globulin.

12 ented by the proper administration of Rhesus immune globulin.

13 l consisting of rituximab and/or intravenous immune globulin.

14 n develop despite treatment with intravenous immune globulin.

15 eceived hepatitis A vaccine and 522 received immune globulin.

16 olated rat anti-B5 mAb (19C2) or by vaccinia immune globulin.

17 nses to conventional therapy and intravenous immune globulin.

18 s, immunosuppressive agents, and intravenous immune globulin.

19 ensing TLR7 and TLR9 proliferate and secrete immune globulins.

20 more potent and broadly reactive hepatitis C immune globulins.

21 ence compromised the safety of the resulting immune globulins.

22 c receptor-blocking monoclonal antibody, and immune globulin (10 mg per milliliter).

23 smapheresis every other day with intravenous immune globulin 100 mg/kg starting 1 week before the sch

24 rea) once weekly for 3 weeks and intravenous immune globulin (2 g per kilogram of body weight) in the

25 rtum cardiomyopathy treated with intravenous immune globulin (2 g/kg) with those of 11 recent histori

26 ceived conventional therapy with intravenous immune globulin, 2 g per kilogram, as well as aspirin, 8

27 vaccine (4.4%) and in 17 contacts receiving immune globulin (3.3%) (relative risk, 1.35; 95% confide

28 of 3 treated) and immunotherapy (intravenous immune globulin, 3 of 4 treated and plasmapheresis, 3 of

29 most promising dose range for intravenous Rh immune globulin (50-75 microg/kg).

30 it is possible to predict the reactivity of immune globulin against divergent lyssaviruses.

31 t of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary

32 screening, including benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of n

33 The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV in

34 3 despite empiric treatment with intravenous immune globulin and methylprednisolone, splenectomy was

35 =0.01 and P<0.001, respectively) between the immune globulin and placebo groups, and immune globulin

36 Postexposure prophylaxis using rabies immune globulin and rabies vaccine is effective in preve

37 in the U.S. study also received intravenous immune globulin and rituximab after transplantation to p

38 suggest that the combination of intravenous immune globulin and rituximab may prove effective as a d

39 lled and received treatment with intravenous immune globulin and rituximab.

40 In addition to hepatitis B immune globulin and vaccination, oral antiviral therapie

41 with PV who required treatment with vaccinia immune globulin and who received 2 investigational agent

42 cury from thimerosal-containing vaccines and immune globulins and deficits in neuropsychological func

43 fever, rates of retreatment with intravenous immune globulin, and numbers of adverse events.

44 The role of corticosteroids, immune globulin, and plasmapheresis is uncertain.

45 tients do not respond to initial intravenous immune globulin, and recommendations for additional ther

46 Hepatitis A vaccine has similar efficacy to immune globulin as postexposure prophylaxis.

47 that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning re

48 nheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence o

49 Eleven patients who received immune globulin became able to walk more easily or witho

50 mide pulse therapy together with intravenous immune globulin before transplant and as part of a cyclo

51 The D+R- patients were also given CMV immune globulin biweekly for 16 weeks.

52 The human hepatitis C immune globulin Civacir is an investigational drug that

53 he association between cytomegalovirus (CMV) immune globulin (CMVIG) and clinical outcomes in pediatr

54 After controlling for CMV immune globulin (CMVIG) prophylaxis, the association bet

55 ults (n = 20) 7 days after administration of immune globulin contained similar antibody levels by imm

56 No effect of immune globulin could be demonstrated in the direct inoc

57 diagnosis vary, and the doses of replacement immune globulin differ.

58 Using equine immune globulin (equine Ig) as a model Ag, we examined t

59 Among patients who received immune globulin first, stiffness scores decreased signif

60 onthly infusion of rituximab and intravenous immune globulin for 4 consecutive months.

61 antiviral therapy alone without hepatitis B immune globulin for chronic hepatitis B patients with pr

62 hemolysis after infusions of intravenous Rh immune globulin for immune thrombocytopenic purpura has

63 n, and it may be a reasonable alternative to immune globulin for postexposure prophylaxis in many sit

64 ry other day plasmapheresis with intravenous immune globulin for the initial week.

65 partum cardiomyopathy, patients treated with immune globulin had a greater improvement in ejection fr

66 Intravenous immune globulin has been reported to improve left ventri

67 were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days a

68 Today, the combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide an

69 long-term antiviral and low-dose hepatitis B Immune globulin (HBIG) can effectively prevent HBV recur

70 Hepatitis B immune globulin (HBIG) dosing regimens have been poorly

71 Hepatitis B immune globulin (HBIG) has been an integral component of

72 Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatiti

73 of antiviral therapy with either hepatitis B immune globulin (HBIg) or lamivudine; however, HBV recur

74 e received high-dose intravenous hepatitis B immune globulin (HBIG) treatment with continued lamivudi

75 been passive immunotherapy with hepatitis B immune globulin (HBIG).

76 venous immune globulin (IGIV) or hepatitis C immune globulin (HCIG), and a third animal was not treat

77 G (IgG) subclasses from polyclonal human HIV immune globulin (HIVIG) in the neutralization of HIV-1 s

78 y by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies

79 IgG, including pharmacologic formulations of immune globulin i.v. (IGIV), contain Abs that specifical

80 the effects of commercial intravenous human immune globulin (i.v.IG) preparations and found that i.v

81 ated against hepatitis A and should be given immune globulin if they used methamphetamine with a case

82 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) are routinely used for measles post

83 Human-plasma-derived immune globulin (IG) is used in augmentation therapy to

84 h later with anti-HCV--negative intravenous immune globulin (IGIV) or hepatitis C immune globulin (H

85 treatment of the initial episode with human immune globulin in addition to ganciclovir.

86 with hepatitis B vaccination and hepatitis B immune globulin in certain endemic regions as well as fa

87 tient selection and delivery of human rabies immune globulin in EDs across a multihospital health sys

88 selection and administration of human rabies immune globulin in the emergency department (ED) setting

89 Since the institution of intravenous immune globulin in the treatment of the disease, outcome

90 In order to understand the role of these immune globulins in the pathogenesis of the disease, it

91 ents were treated with high-dose intravenous immune globulin infusions (2 g/kg).

92 Drug Administration (FDA) licensed Rh(o)(D) immune globulin intravenous (anti-D IGIV) on March 24, 1

93 Rh(o)(D) immune globulin intravenous (anti-D IGIV) was licensed b

94 We created the orphan drug Human Botulism Immune Globulin Intravenous (Human) (BIG-IV), which neut

95 affects mnAb levels in contemporary lots of Immune Globulin Intravenous (Human) (IGIV).

96 hether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and

97 ly improved after administration of vaccinia immune globulin intravenous (VIGIV) highlighting its use

98 imat, cidofovoir, brincidofovir and vaccinia immune globulin intravenous may be used for systemic inf

99 as tecovirimat, brincidofovir, and vaccinia immune globulin intravenous, are available through expan

100 The use of passive immune globulin is a crucial component of rabies postexp

101 ow platelet counts and confirmed that anti-D immune globulin is a front-line treatment option.

102 Intravenous immune globulin is a well-tolerated and effective, albei

103 Immune modulatory therapy with immune globulin is an effective therapy for Kawasaki dis

104 accumulating to indicate that intravenous Rh immune globulin is as effective, probably safer, and eas

105 The combination of rituximab and intravenous immune globulin is effective in patients with refractory

106 antiviral therapy alone without hepatitis B immune globulin is highly effective in preventing HBV re

107 Although intravenous immune globulin is the mainstay of initial treatment, th

108 thorough characterization of anti-SARS-CoV-2 immune globulin isotypes in kidney transplant recipients

109 ory syndrome coronavirus 2 (anti-SARS-CoV-2) immune globulin isotypes in organ transplant recipients

110 to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and

111 Desensitization with intravenous immune globulin (IVIG) and rituximab improves transplant

112 alized linear models to evaluate intravenous immune globulin (IVIG) as a reference, as compared with

113 We now report that intravenous immune globulin (IVIG) derived from pools of human plasm

114 Intravenous immune globulin (IVIG) for the treatment of dermatomyosi

115 While treatment with intravenous immune globulin (IVIG) has been reported, safety in a pr

116 High-dose intravenous immune globulin (IVIg) has emerged as an important thera

117 ppressive mechanism of action of intravenous immune globulin (IVIG) has remained enigmatic despite th

118 as designed to determine whether intravenous immune globulin (IVIG) improves left ventricular ejectio

119 ollowed by immunomodulation with intravenous immune globulin (IVIG) in select cases; the implementati

120 (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered to reduce the

121 The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommend

122 herapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared

123 Intravenous immune globulin (IVIG) suppresses autoantibody-mediated

124 All 3 patients responded to intravenous immune globulin (IVIG) treatment.

125 In living-donor recipients, intravenous immune globulin (IVIG) was added to the CMX evaluation t

126 gen (SLA) class I antibodies or pooled human immune globulin (IVIg) were used to reverse the effects

127 D.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x

128 ng human immunoglobulin G (IgG) (intravenous immune globulin [IVIG]), AAV-Go.1 had higher resistance

129 iciency characterized by low levels of serum immune globulins, lack of Ab, and reduced numbers of CD2

130 Pretreatment with bacterial polysaccharide immune globulin led to a significant reduction in coloni

131 h CVID who have mutations in TACI but normal immune globulin levels still have detectable in vitro B-

132 ilated cardiomyopathy treated with high-dose immune globulin, LVEF improved 17 EF units.

133 Immune globulins made from anti-HCV-positive plasma and

134 Using human immune globulins made from antihepatitis C virus (HCV)-p

135 eated with glucocorticoids (n=106, [49.5%]), immune globulin (n=39 [18.2%]), and thrombopoietin recep

136 luate the effect of therapy with intravenous immune globulin on recovery of left ventricular function

137 Optimal use of immune globulin or CMV-specific T cells for prevention o

138 ies, in random order, to receive intravenous immune globulin or placebo for three months, followed by

139 Patients who received human rabies immune globulin or rabies vaccine in the ED from January

140 30% after the second infusion of intravenous immune globulin (P<0.001 for the comparison with the pre

141 lovir, adefovir, respiratory syncytial virus immune globulin, palivizumab, and imiquimod are discusse

142 le-center study examined whether intravenous immune globulin plus rituximab could reduce anti-HLA ant

143 corticosteroids, cidofovir, and intravenous immune globulin, PML progressed rapidly, rendering the p

144 s 412 to 426, as it did with an HCV-specific immune globulin preparation, which was derived from the

145 ng and protective antibodies in experimental immune globulin preparations made from anti-HCV-positive

146 containing preservative used in vaccines and immune globulin preparations, is associated with neurops

147 Immune globulins prepared by ethanol fractionation of pl

148 long been considered safe until a commercial immune globulin product, Gammagard, prepared from plasma

149 ing in cytokine secretion, IgG class switch, immune globulin production, and potentially, the preserv

150 identification of thrombogenic impurities in immune globulin products, which were associated with thr

151 tive measurement of thrombogenic activity in immune globulin products.

152 nsible for the safety testing and release of immune globulin products.

153 randomized, placebo-controlled trial of CMV immune globulin prophylaxis.

154 groups indicate that hepatitis A vaccine and immune globulin provided good protection after exposure.

155 Full adherence to 6 human rabies immune globulin quality indicators: patient selection, d

156 nsplant patients, and valganciclovir and CMV immune globulin reduce rejection rates and cardiovascula

157 ibodies have been achieved through use of Rh immune globulin (RhIg), a polyclonal antibody preparatio

158 Polyclonal anti-D (Rh immune globulin [RhIg]) therapy has mitigated hemolytic

159 standard of care treatment with intravenous immune globulin + rituximab with or without plasma excha

160 were given respiratory syncytial virus (RSV) immune globulin (RSVIG) at the time of transplantation a

161 Research on vaccine and immune globulin safety remains scarce for children and a

162 Titration of 62 immune globulin samples (prepared from 1957 to 1994) sho

163 nization (WHO) international standard rabies immune globulins (SRIGs) allow the standardisation of th

164 munodeficiency who was receiving intravenous immune globulin suddenly had paralysis of all four limbs

165 fants, of whom four discontinued intravenous immune globulin supplementation; three of these four inf

166 bo-controlled trial of cytomegalovirus (CMV) immune globulin that included 146 patients who underwent

167 at immunity may be augmented by vaccines and immune globulins that include strong antibody responses

168 ong-term protection conferred by hepatitis A immune globulin, the efficacy of a single injection (20

169 Over the past decade, intravenous immune globulin therapy (IVIG) has gained widespread use

170 inistration but dropped significantly during immune globulin therapy (P=0.01).

171 Anti-GAD65 antibody titers declined after immune globulin therapy but not after placebo administra

172 tivity scores decreased substantially during immune globulin therapy but rebounded during placebo adm

173 thylprednisolone to conventional intravenous immune globulin therapy for the routine primary treatmen

174 the immune globulin and placebo groups, and immune globulin therapy had a significant direct treatme

175 remains unknown, but fortunately intravenous immune globulin therapy has proved to be effective at re

176 The role of immune globulin therapy in adults with this disorder has

177 The effectiveness of intravenous immune globulin therapy in this disorder should be evalu

178 or Kawasaki disease resistant to intravenous immune globulin therapy is an area of research and contr

179 stemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities d

180 d the administration of low-dose intravenous immune globulin to desensitize 211 HLA-sensitized patien

181 we report a novel approach using intravenous immune globulin to modulate anti-HLA antibody and improv

182 Despite the widespread use of Rh immune globulin to prevent pregnancy associated anti-D a

183 al or neonatal disease and candidates for Rh-immune globulin; transplantation for bone marrow donor s

184 The duration of the beneficial effects of immune globulin varied from six weeks to one year.

185 Penicillin, clindamycin, and intravenous immune globulin (Venoglobulin-S; IVIG) alone and in comb

186 neutralizing determinants and that vaccinia immune globulin (VIG) derived from Dryvax recipients con

187 Vaccinia immune globulin (VIG) has been used therapeutically to t

188 h improved safety profiles, and new vaccinia immune globulin (VIG) products, there is an immediate ne

189 Intravenous Rh [corrected] immune globulin was licensed by the U.S. Food and Drug a

190 r ejection fraction in patients treated with immune globulin was significantly greater than in the co

191 9 months post-OLT, and prophylaxis with HBV immune globulin was then established.

192 modulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids i

193 IV-1-infected patients as well as pooled HIV immune globulin were selectively depleted of antibodies

194 monoclonal antibodies 2F5 and 2G12, and HIV immune globulin were tested.

195 lar damage in dermatomyositis by intravenous immune globulin which appears to intercept the assembly

196 A virus has not been compared directly with immune globulin, which is known to be highly effective i

197 tinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SI

198 comparing conventional doses of intravenous immune globulin with the most promising dose range for i

199 e-appropriate dose of hepatitis A vaccine or immune globulin within 14 days after exposure to patient